JP7711095B2 - PD-1とTGF-βに対する二機能性タンパク質 - Google Patents

PD-1とTGF-βに対する二機能性タンパク質

Info

Publication number
JP7711095B2
JP7711095B2 JP2022565971A JP2022565971A JP7711095B2 JP 7711095 B2 JP7711095 B2 JP 7711095B2 JP 2022565971 A JP2022565971 A JP 2022565971A JP 2022565971 A JP2022565971 A JP 2022565971A JP 7711095 B2 JP7711095 B2 JP 7711095B2
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
acid sequence
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022565971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523083A5 (cg-RX-API-DMAC7.html
JP2023523083A (ja
Inventor
ジャオ,ウェイ
リ,インチュン
リュ,ハイリ
シェ,リャンシャン
チャン,チェウェン
チン,ユ
チャン,シーチュエン
チェン,ヤンジュ
リュ,ペン
リ,ティエンティエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2023523083A publication Critical patent/JP2023523083A/ja
Publication of JP2023523083A5 publication Critical patent/JP2023523083A5/ja
Priority to JP2025115631A priority Critical patent/JP2025148434A/ja
Application granted granted Critical
Publication of JP7711095B2 publication Critical patent/JP7711095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
JP2022565971A 2020-04-29 2021-04-26 PD-1とTGF-βに対する二機能性タンパク質 Active JP7711095B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115631A JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010359751 2020-04-29
CN202010359751.8 2020-04-29
PCT/CN2021/089837 WO2021218895A1 (zh) 2020-04-29 2021-04-26 针对PD-1和TGF-β的双功能蛋白

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115631A Division JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Publications (3)

Publication Number Publication Date
JP2023523083A JP2023523083A (ja) 2023-06-01
JP2023523083A5 JP2023523083A5 (cg-RX-API-DMAC7.html) 2024-05-07
JP7711095B2 true JP7711095B2 (ja) 2025-07-22

Family

ID=78331777

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565971A Active JP7711095B2 (ja) 2020-04-29 2021-04-26 PD-1とTGF-βに対する二機能性タンパク質
JP2025115631A Pending JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115631A Pending JP2025148434A (ja) 2020-04-29 2025-07-09 PD-1とTGF-βに対する二機能性タンパク質

Country Status (9)

Country Link
US (1) US12668633B2 (cg-RX-API-DMAC7.html)
EP (1) EP4144763A4 (cg-RX-API-DMAC7.html)
JP (2) JP7711095B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230003178A (cg-RX-API-DMAC7.html)
AU (1) AU2021263650A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181579A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013620A (cg-RX-API-DMAC7.html)
WO (1) WO2021218895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
WO2023208191A1 (zh) * 2022-04-29 2023-11-02 广东菲鹏制药股份有限公司 一种重组抗体及其应用
WO2025251034A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Purification method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533475A (ja) 2016-08-23 2019-11-21 康方▲藥▼▲業▼有限公司Akeso Pharmaceuticals, Inc. 抗ctla4−抗pd−1二機能性抗体、その医薬組成物および使用
WO2020043184A1 (zh) 2018-08-30 2020-03-05 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD120103A1 (cg-RX-API-DMAC7.html) 1975-07-07 1976-05-20
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
ES2820768T3 (es) * 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110050000B (zh) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
BR112020022145A2 (pt) 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
CN112672753B (zh) 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN110734498A (zh) 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
JP7495489B2 (ja) * 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー,リミティド PD-1およびTGFβを標的化する組換えタンパク質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533475A (ja) 2016-08-23 2019-11-21 康方▲藥▼▲業▼有限公司Akeso Pharmaceuticals, Inc. 抗ctla4−抗pd−1二機能性抗体、その医薬組成物および使用
WO2020043184A1 (zh) 2018-08-30 2020-03-05 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
US20230235057A1 (en) 2023-07-27
CA3181579A1 (en) 2021-11-04
WO2021218895A1 (zh) 2021-11-04
KR20230003178A (ko) 2023-01-05
BR112022022020A2 (pt) 2023-01-31
EP4144763A4 (en) 2024-05-29
JP2025148434A (ja) 2025-10-07
US12668633B2 (en) 2026-06-30
MX2022013620A (es) 2023-01-30
EP4144763A1 (en) 2023-03-08
AU2021263650A1 (en) 2023-01-19
JP2023523083A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
CN112940134B (zh) 针对PD-1和TGF-β的双功能蛋白
EP3733715A1 (en) Triabody, preparation method and use thereof
JP6124377B2 (ja) 新規抗dr5抗体
JP2025148434A (ja) PD-1とTGF-βに対する二機能性タンパク質
JP2024534545A (ja) インターロイキン2変異体およびその融合タンパク質
JP2018531219A (ja) Pd−l1抗体
JP2018531219A6 (ja) Pd−l1抗体
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
JP2024534795A (ja) 二重特異性抗体およびその使用
JP7288984B2 (ja) Pd-1及びpd-l1を標的とする四価二重特異性抗体
JP2023544143A (ja) 抗クローディン18.2および抗cd3二重特異性抗体およびその使用
JP2022513228A (ja) 抗ペリオスチン抗体及びその使用
US20220289825A1 (en) FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF
TW202400662A (zh) 結合pd-l1和cldn18.2的抗體及其用途
RU2843303C1 (ru) БИФУНКЦИОНАЛЬНЫЙ БЕЛОК ПРОТИВ PD-1 И TGF-β
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
HK40081562A (en) Bifunctional protein aiming at pd-1 and tgf-beta
US20250289901A1 (en) Anti-cd3e/bcma bispecific antibody and use thereof
HK40076695A (en) FUSION PROTEIN TARGETING PD-L1 AND TGF-β AND USE THEREOF
CN122003440A (zh) 抗muc16抗体及其用途
WO2025252212A1 (zh) 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
CA3215850A1 (en) Composition comprising an ige antibody
JP2024519612A (ja) 抗cd40抗体及びその用途
CN118725133A (zh) 双特异性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250709

R150 Certificate of patent or registration of utility model

Ref document number: 7711095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150